PK MED, a Lyon, France-based biotechnology company, received €1.5M in non-dilutive DeepTech financing.
Bpifrance provided the funding.
The company intends to use the funds to accelerate its project PKM-02, an innovative cell-homing technology aiming to enhance bone marrow transplantation in several diseases with high unmet medical need, such as leukemias and hemoglobinopathies.
Led by CEO Gauthier Pouliquen, PK MED is a biotechnology company, founded in 2019 by Truffle Capital, developing injectable smart implants for drug release in rheumatology and cell homing for bone marrow transplantation. Its expertise and technological know-how enable evolving existing systemic treatments into new patented local therapies.
Its PKM-02 project is based on the development of a therapeutic implant locally injected into the patient’s bone marrow prior to allogeneic HSCT. This drug-based technology, combined with a biodegradable scaffold, is aimed at increasing the homing of the transplanted cells, as well as their subsequent engraftment. PKM-02 has shown in vitro results, and PK MED is currently initiating preclinical studies.
FinSMEs
24/07/2024